Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
about
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataAssessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical dataAn S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statinsMechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Dealing with the complex drug-drug interactions: towards mechanistic models.Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.Renal Drug Transporters and Drug Interactions.Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies.Application of PBPK modelling in drug discovery and development at Pfizer.Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions.Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib.Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.Hepatic transporter drug-drug interactions: an evaluation of approaches and methodologies.CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect.Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model.Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses
P2860
Q27009128-7A9055A8-8843-4CBC-A1A8-5676B97A1AB9Q30688345-50A29924-0349-478F-BA67-8EFB4DBC7301Q30856965-E3C31965-65D6-4B73-9124-B8C07026A380Q31123470-9790567E-85E2-46B0-BD93-F06D7B2F5707Q34571105-FC19E03D-2A9B-470C-A945-7C373AEC33A5Q36303746-42E27EC9-A9B9-4432-A6F8-7157BAFB05A6Q37207816-C470D137-3E3B-4D38-A2D4-282DC5B7B01CQ37325598-92ADB191-FD1B-4066-8EB4-940829734824Q37965706-CE76C6DB-A5CB-4F9A-B8F7-F0376DAB76E6Q37989979-0000BB05-42AD-4E82-A2A5-8FB2D25A6DAFQ38075057-79A35279-DEC1-4705-8208-9A1DE637CDDDQ38233298-15B6D6A9-161E-4F03-9141-075EB1DE2593Q38302225-32C61153-DA63-4882-83B3-8166C679579DQ38836056-A31089BB-D050-4DDB-B58E-C71D25A58EB7Q39140289-715B3E4F-0613-48D5-B5C5-CDC1F836C319Q39212609-61674E80-428E-4CEC-9AB2-B194B33BD36CQ39624755-1E0FD5F8-910C-449D-8E57-76E2F6195729Q39692575-6B5027CE-5A7B-432C-865F-65BB0B3A02DEQ40346427-29312673-EC5E-46EB-A15A-4D4D191D246EQ41072555-AA361C75-AD1C-454E-9ABD-DF520F2FE629Q41451834-263C6582-68DF-4664-952C-D74B32577675Q46135472-F67B4226-FD6C-4D6D-9353-7315EAD03552Q47420860-1D8665E1-2A75-440D-8A19-D4531B1B93A4Q47792940-325ED5C4-C834-4E1E-8835-9D27583D5726Q47924035-A5246E09-8E01-415F-81E0-D7C7A11F1DCFQ48010621-77E285C2-B349-4DEB-9965-80B7399279C6Q49345918-584946AB-E306-4188-BE43-2AD85B8529C3Q57825117-017D4696-71A4-47BA-BA63-D7879C87EEFC
P2860
Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Assessment of algorithms for p ...... of dynamic and static models.
@ast
Assessment of algorithms for p ...... of dynamic and static models.
@en
Assessment of algorithms for p ...... of dynamic and static models.
@nl
type
label
Assessment of algorithms for p ...... of dynamic and static models.
@ast
Assessment of algorithms for p ...... of dynamic and static models.
@en
Assessment of algorithms for p ...... of dynamic and static models.
@nl
prefLabel
Assessment of algorithms for p ...... of dynamic and static models.
@ast
Assessment of algorithms for p ...... of dynamic and static models.
@en
Assessment of algorithms for p ...... of dynamic and static models.
@nl
P2093
P2860
P1476
Assessment of algorithms for p ...... n of dynamic and static models
@en
P2093
Amin Rostami-Hodjegan
Eleanor J Guest
Geoffrey T Tucker
J Brian Houston
Karen Rowland-Yeo
P2860
P356
10.1111/J.1365-2125.2010.03799.X
P407
P577
2011-01-01T00:00:00Z